ATE199398T1 - Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein - Google Patents
Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen proteinInfo
- Publication number
- ATE199398T1 ATE199398T1 AT98112614T AT98112614T ATE199398T1 AT E199398 T1 ATE199398 T1 AT E199398T1 AT 98112614 T AT98112614 T AT 98112614T AT 98112614 T AT98112614 T AT 98112614T AT E199398 T1 ATE199398 T1 AT E199398T1
- Authority
- AT
- Austria
- Prior art keywords
- signal peptide
- human protein
- secretion
- gamma interferon
- interferon signal
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
- A61K9/5184—Virus capsids or envelopes enclosing drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13041—Use of virus, viral particle or viral elements as a vector
- C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
- C12N2740/13051—Methods of production or purification of viral material
- C12N2740/13052—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S930/00—Peptide or protein sequence
- Y10S930/01—Peptide or protein sequence
- Y10S930/14—Lymphokine; related peptides
- Y10S930/144—Tumor necrosis factor
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Botany (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Optics & Photonics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42698689A | 1989-10-24 | 1989-10-24 | |
US47416990A | 1990-02-02 | 1990-02-02 | |
US48870690A | 1990-03-02 | 1990-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE199398T1 true ATE199398T1 (de) | 2001-03-15 |
Family
ID=27411529
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT98112614T ATE199398T1 (de) | 1989-10-24 | 1990-10-23 | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
AT91901031T ATE212672T1 (de) | 1989-10-24 | 1990-10-23 | System zur freisetzung von infektiösen proteinen |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT91901031T ATE212672T1 (de) | 1989-10-24 | 1990-10-23 | System zur freisetzung von infektiösen proteinen |
Country Status (8)
Country | Link |
---|---|
US (6) | US5324655A (de) |
EP (2) | EP0497922B1 (de) |
JP (2) | JP3203599B2 (de) |
AT (2) | ATE199398T1 (de) |
AU (2) | AU661652B2 (de) |
CA (1) | CA2067821A1 (de) |
DE (2) | DE69033710T2 (de) |
WO (1) | WO1991006658A2 (de) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
US6133029A (en) * | 1988-03-21 | 2000-10-17 | Chiron Corporation | Replication defective viral vectors for infecting human cells |
US5997859A (en) * | 1988-03-21 | 1999-12-07 | Chiron Corporation | Method for treating a metastatic carcinoma using a conditionally lethal gene |
US6569679B1 (en) | 1988-03-21 | 2003-05-27 | Chiron Corporation | Producer cell that generates adenoviral vectors encoding a cytokine and a conditionally lethal gene |
US5662896A (en) | 1988-03-21 | 1997-09-02 | Chiron Viagene, Inc. | Compositions and methods for cancer immunotherapy |
ATE199398T1 (de) * | 1989-10-24 | 2001-03-15 | Chiron Corp | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
CA2042093C (en) * | 1990-05-09 | 2002-12-24 | Gyula Hadlaczky | Cell line carrying an excess of mammalian centromeres |
WO1991019803A1 (en) * | 1990-06-19 | 1991-12-26 | Applied Biotechnology, Incorporated | Self assembled, defective, nonself-propagating viral particles |
US5817491A (en) * | 1990-09-21 | 1998-10-06 | The Regents Of The University Of California | VSV G pseusdotyped retroviral vectors |
WO1992014829A1 (en) * | 1991-02-19 | 1992-09-03 | The Regents Of The University Of California | Viral particles having altered host range |
US5512421A (en) * | 1991-02-19 | 1996-04-30 | The Regents Of The University Of California | Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors |
WO1993010218A1 (en) * | 1991-11-14 | 1993-05-27 | The United States Government As Represented By The Secretary Of The Department Of Health And Human Services | Vectors including foreign genes and negative selective markers |
US5436243A (en) * | 1993-11-17 | 1995-07-25 | Research Triangle Institute Duke University | Aminoanthraquinone derivatives to combat multidrug resistance |
KR960703172A (ko) | 1993-11-18 | 1996-06-19 | 스티븐 제이. 멘토 | 조건적으로 치사적인 유전자를 활용하기 위한 조성물 및 방법(Compositions and methods for utilizing conditionally lethal genes) |
US5807746A (en) * | 1994-06-13 | 1998-09-15 | Vanderbilt University | Method for importing biologically active molecules into cells |
WO2000066608A1 (en) * | 1999-04-30 | 2000-11-09 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US6599719B2 (en) | 1994-11-07 | 2003-07-29 | Human Genome Sciences, Inc. | Nucleic acid molecules encoding tumor necrosis factor-gamma-alpha |
US20030198640A1 (en) * | 1994-11-07 | 2003-10-23 | Human Genome Sciences, Inc. | Methods and compositions for treating inflammatory bowel diseases relating to human tumor necrosis factor-gamma-beta |
US6824767B2 (en) | 1994-11-07 | 2004-11-30 | Human Genome Sciences, Inc. | Tumor necrosis factor-gamma |
US5665591A (en) * | 1994-12-06 | 1997-09-09 | Trustees Of Boston University | Regulation of smooth muscle cell proliferation |
US6025155A (en) * | 1996-04-10 | 2000-02-15 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6077697A (en) | 1996-04-10 | 2000-06-20 | Chromos Molecular Systems, Inc. | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US20020160970A1 (en) * | 1996-04-10 | 2002-10-31 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US20030033617A1 (en) * | 1996-04-10 | 2003-02-13 | Gyula Hadlaczky | Artificial chromosomes, uses thereof and methods for preparing artificial chromosomes |
US6544523B1 (en) | 1996-11-13 | 2003-04-08 | Chiron Corporation | Mutant forms of Fas ligand and uses thereof |
US20020111325A1 (en) * | 1997-11-03 | 2002-08-15 | Human Genome Sciences, Inc. | VEGI, an inhibitor of angiogenesis and tumor growth |
US7049410B2 (en) * | 1999-05-14 | 2006-05-23 | Majumdar Adhip P N | Antibodies to a novel EGF-receptor related protein (ERRP) |
AU5003200A (en) | 1999-05-14 | 2000-12-05 | United States Of America As Represented By The Department Of Veterans Affairs, The | Isolation and characterization of epidermal growth factor related protein |
US20030235594A1 (en) * | 1999-09-14 | 2003-12-25 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
US9289487B2 (en) * | 1999-09-14 | 2016-03-22 | Antigen Express, Inc. | II-key/antigenic epitope hybrid peptide vaccines |
US6432409B1 (en) * | 1999-09-14 | 2002-08-13 | Antigen Express, Inc. | Hybrid peptides modulate the immune response |
US20070172449A1 (en) * | 2000-03-02 | 2007-07-26 | Xencor, Inc. | TNF-alpha VARIANT FORMULATIONS FOR THE TREATMENT OF TNF-alpha RELATED DISORDERS |
US7662367B2 (en) * | 2000-03-02 | 2010-02-16 | Xencor, Inc. | Pharmaceutical compositions for the treatment of TNF-α related disorders |
US7446174B2 (en) | 2001-03-02 | 2008-11-04 | Xencor, Inc. | Protein based TNF-α variants for the treatment of TNF-α related disorders |
US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
US7687461B2 (en) * | 2000-03-02 | 2010-03-30 | Xencor, Inc. | Treatment of TNF-α related disorders with TNF-α variant proteins |
US7056695B2 (en) | 2000-03-02 | 2006-06-06 | Xencor | TNF-α variants |
US7244823B2 (en) * | 2000-03-02 | 2007-07-17 | Xencor | TNF-alpha variants proteins for the treatment of TNF-alpha related disorders |
US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
AU1844702A (en) * | 2000-09-28 | 2002-04-08 | Bioriginal Food And Science Co | Fad4, fad5, fad5-2, and fad6, novel fatty acid desaturase family members and uses thereof |
US20030086903A1 (en) * | 2001-11-02 | 2003-05-08 | Genvec, Inc. | Therapeutic regimen for treating cancer |
US7179645B2 (en) * | 2002-09-24 | 2007-02-20 | Antigen Express, Inc. | Ii-Key/antigenic epitope hybrid peptide vaccines |
CA2499123A1 (en) | 2002-09-17 | 2004-04-15 | Antigen Express, Inc. | Ii-key/antigenic epitope hybrid peptide vaccines |
ATE472556T1 (de) * | 2002-12-02 | 2010-07-15 | Amgen Fremont Inc | Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen |
US20040121971A1 (en) * | 2002-12-20 | 2004-06-24 | Gang Chen | Therapeutic use of tumor necrosis factor-alpha mutein |
DE10362104B4 (de) * | 2003-08-29 | 2008-02-14 | Kist-Europe Forschungsgesellschaft Mbh | Zellprozessor zur Krankheitsbehandlung |
GB0325494D0 (en) * | 2003-10-31 | 2003-12-03 | Sbl Vaccin Ab | Expression system |
ES2340038T3 (es) * | 2003-11-14 | 2010-05-28 | Genvec, Inc. | Composicion farmaceutica para tratar cancer de pancreas localmente avanzado (cpla) no extirpable. |
WO2006042017A2 (en) | 2004-10-06 | 2006-04-20 | University Of Rochester | Treatment of pulmonary hypertension using an agent that inhibits a tissue factor pathway |
EP2110667A1 (de) | 2005-01-20 | 2009-10-21 | University Of Rochester | Mit Thioredoxin interagierendes Protein (TXNIP) als Regulator der Gefäßfunktion |
SI2567976T1 (sl) | 2005-03-23 | 2017-11-30 | Genmab A/S | Protitelesa usmerjena proti cd38 za zdravljenje multiplega mieloma |
DK2222697T3 (da) | 2007-11-01 | 2013-03-11 | Perseid Therapeutics Llc | Immunsuppressive polypeptider og nukleinsyrer |
US20110045058A1 (en) * | 2007-11-20 | 2011-02-24 | Beth Israel Deaconess Medical Center | Transfection reagent |
CA2750922A1 (en) * | 2009-01-28 | 2010-08-05 | Antigen Express, Inc. | Li-key hybrid peptides that modulate the immune response to influenza |
WO2010107991A2 (en) | 2009-03-18 | 2010-09-23 | Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Use of ixolaris, a tissue factor inhibitor, for the treatment and prevention of cancer |
EA032675B1 (ru) | 2009-06-10 | 2019-07-31 | Нью-Йорк Юниверсити | Способ и композиции для лечения болезни альцгеймера и других таупатий |
US9605844B2 (en) * | 2009-09-01 | 2017-03-28 | Cree, Inc. | Lighting device with heat dissipation elements |
ES2743507T3 (es) | 2009-11-02 | 2020-02-19 | Univ Emory | Inmunoterapia resistente a fármaco para el tratamiento de un cáncer |
US20130344053A1 (en) | 2010-12-28 | 2013-12-26 | University Of Rochester | Methods of Modifying Insulin Signaling Using Biliverdin Reductase (BVR) and BVR Derived Peptides |
HUE051021T2 (hu) | 2011-09-07 | 2021-01-28 | Sinai School Medicine | Ceramidáz és sejtek differenciálódása |
US9694050B2 (en) | 2012-10-21 | 2017-07-04 | University Of Rochester | THY1 (CD90) as a novel therapy to control adipose tissue accumulation |
EP2992112B1 (de) | 2013-04-22 | 2020-06-03 | Icahn School of Medicine at Mount Sinai | Mutationen in pdgfrb und notch3 als ursachen für autosomale dominante infantile myofibromatose |
EP4295914A3 (de) | 2015-09-03 | 2024-04-10 | The UAB Research Foundation | Gentechnologisch hergestellte arzneimittelresistente t-zellen und verfahren zur verwendung davon |
US11273151B2 (en) | 2015-11-04 | 2022-03-15 | Icahn School Of Medicine At Mount Sinai | Methods of treating tumors and cancer, and identifying candidate subjects for such treatment |
US11246868B2 (en) | 2016-04-26 | 2022-02-15 | Icahn School Of Medicine At Mount Sinai | Treatment of hippo pathway mutant tumors and methods of identifying subjects as candidates for treatment |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4405712A (en) * | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
US4678751A (en) * | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
US4769330A (en) * | 1981-12-24 | 1988-09-06 | Health Research, Incorporated | Modified vaccinia virus and methods for making and using the same |
US4603112A (en) * | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
IL68366A (en) * | 1982-04-15 | 1990-08-31 | Genentech Inc | Process for expressing a gene encoding a protein comprising the enzymatic portion of human urokinase in a microorganism or cell culture |
US4650764A (en) * | 1983-04-12 | 1987-03-17 | Wisconsin Alumni Research Foundation | Helper cell |
US4518584A (en) * | 1983-04-15 | 1985-05-21 | Cetus Corporation | Human recombinant interleukin-2 muteins |
GB8324800D0 (en) * | 1983-09-15 | 1983-10-19 | Pasteur Institut | Antigens |
FR2559159B1 (fr) * | 1984-02-02 | 1986-09-12 | Inst Nat Sante Rech Med | Vecteurs viraux de clonage et d'expression d'une proteine dans une cellule eucaryote, comportant au moins une partie du genome d'un retro-virus; cellules eucaryotes transfectees; procede utilisant de telles cellules et proteines obtenues |
US5288852A (en) * | 1984-03-06 | 1994-02-22 | Dainippon Pharmaceutical Co., Ltd. | Human tumor necrosis factor polypeptides |
US4663281A (en) * | 1984-03-22 | 1987-05-05 | Mass Institute Of Technology | Enhanced production of proteinaceous materials in eucaryotic cells |
US4879226A (en) * | 1984-04-06 | 1989-11-07 | Asahi Kasei Kogyo Kabushiki Kaisha | Novel human physiologically active polypeptide |
US4738922A (en) * | 1984-05-25 | 1988-04-19 | Dana Farber Cancer Institute | Trans-acting transcriptional factors |
AU4404785A (en) * | 1984-05-25 | 1985-12-31 | Dana-Farber Cancer Institute, Inc. | Ltr vectors, methods of preparation and use |
WO1985005618A1 (en) * | 1984-06-06 | 1985-12-19 | Takeda Chemical Industries, Ltd. | Process for preparing interferon derivative |
WO1986000930A1 (en) * | 1984-07-20 | 1986-02-13 | Worcester Foundation For Experimental Biology | Retroviral vaccines and vectors and methods for their construction |
EP0192658A4 (de) * | 1984-07-30 | 1987-07-13 | Salk Inst For Biological Studi | Retrovirale gentransfervektoren. |
GB8424757D0 (en) * | 1984-10-01 | 1984-11-07 | Pasteur Institut | Retroviral vector |
US4677064A (en) * | 1984-11-09 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
US4677063A (en) * | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
AU589919B2 (en) * | 1984-10-15 | 1989-10-26 | Cetus Corp | Human tumor necrosis factor |
US4725669A (en) * | 1984-11-09 | 1988-02-16 | President And Fellows Of Harvard College | Assay for detecting infection by human T-cell lymphotropic virus-III |
ATE73856T1 (de) * | 1984-12-21 | 1992-04-15 | Biogen Inc | Reinigung, herstellung und verwendung von tumor- nekrosisfaktoren. |
US4847201A (en) * | 1985-02-05 | 1989-07-11 | Cetus Corporation | DNA encoding for CSF-1 and accompanying recombinant systems |
EP0196864A3 (de) * | 1985-03-25 | 1988-03-23 | Cetus Corporation | Behandlung und Sekretion von rekombinanten Proteinen mittels alkalischer Phosphatase, dazu verwendbare DNA-Sequenzen und mittels dieser Sequenzen transformierte Zellen |
US4980286A (en) * | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
DE3681787D1 (de) * | 1985-07-05 | 1991-11-07 | Whitehead Biomedical Inst | Expression von fremdem genetischem material in epithelzellen. |
US5604293A (en) * | 1985-09-12 | 1997-02-18 | Scios Inc. | Recombinant human basic fibroblast growth factor |
US4894439A (en) * | 1986-05-22 | 1990-01-16 | Cetus Corporation | N-terminal derivatives of tumor necrosis factor purified by microporous PTFE membranes |
US5091309A (en) * | 1986-01-16 | 1992-02-25 | Washington University | Sindbis virus vectors |
EP0247906B1 (de) * | 1986-02-04 | 1994-12-28 | Mizuno, Den'Ichi | Für Antitumor-Polypeptide kodierende DNS, die Polypeptide und diese Polypeptide enthaltenden Antitumor-Wirkstoffe |
US4822605A (en) * | 1986-02-18 | 1989-04-18 | Exovir, Inc. | Compositions and methods employing the same for the treatment of viral and cancerous skin lesions and the like |
EP0237676B1 (de) * | 1986-03-07 | 1998-08-12 | Chiron Corporation | Rekombinantes Ricin-Toxin |
US5206352A (en) * | 1986-03-28 | 1993-04-27 | Board Of Trustees Of The University Of Illinois | Compositions for clones containing DNA sequences associated with multidrug resistance in human cells |
US4752565A (en) * | 1986-04-07 | 1988-06-21 | The United States Of America As Represented By The Department Of Health And Human Services | Cell line producing AIDS viral antigens without producing infectious virus particles |
FR2606029B2 (fr) * | 1986-04-08 | 1989-02-03 | Transgene Sa | Vecteur viral et adn recombinant codant pour une glycoproteine du virus agent causal du s.i.d.a., culture cellulaire infectee par ce vecteur, procede de preparation de la glycoproteine, glycoproteine obtenue, vaccin et anticorps obtenus |
CA1310924C (en) * | 1986-04-24 | 1992-12-01 | Francis P. Mccormick | Infective drug delivery system |
US4861719A (en) * | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4868119A (en) * | 1986-12-11 | 1989-09-19 | Genetics Institute, Inc. | Hematopoietic growth factors |
EP0251037B1 (de) * | 1986-06-20 | 1994-06-15 | Dainippon Pharmaceutical Co., Ltd. | Polypeptid-Mutanten des menschlichen TNF und für diese Mutanten codierende DNS |
JPS6332486A (ja) * | 1986-07-25 | 1988-02-12 | Teijin Ltd | 新規生理活性ポリペプチド |
FR2606030B1 (fr) * | 1986-10-31 | 1989-10-20 | Pasteur Institut | Retrovirus recombinant defectif, son procede de fabrication et ses applications, notamment pour l'etude de l'interaction des retrovirus sauvages avec des lignees cellulaires infectables par celui-ci |
EP0832981A1 (de) * | 1987-02-17 | 1998-04-01 | Pharming B.V. | DNA-Sequenzen die Proteine zwecks effizienter Abscheidung zur Milchdrüse leiten |
AU1346488A (en) * | 1987-02-26 | 1988-09-26 | Cetus Corporation | Arginine-depleted human tumor necrosis factor |
US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
US4980289A (en) * | 1987-04-27 | 1990-12-25 | Wisconsin Alumni Research Foundation | Promoter deficient retroviral vector |
ATE126534T1 (de) * | 1987-05-29 | 1995-09-15 | Dana Farber Cancer Inst Inc | Cis-wirkung-repressionen-sequenzen, cis-wirkung- antirepressionen-sequenzen, vektoren, verfahren zur vorbereitung und anwendung. |
WO1988010302A1 (en) * | 1987-06-17 | 1988-12-29 | Teijin Limited | Novel plasmid, microbial cells, process for preparing polypeptide with oncostatic activity, and secreted polypeptide with oncostatic activity |
US4873316A (en) * | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
EP0300422B1 (de) * | 1987-07-21 | 1992-12-02 | The Du Pont Merck Pharmaceutical Company | Verfahren für die Herstellung von in tierischen Zellen stabilen und lebensfähigen rekombinanten viralen Vektoren |
US5306631A (en) * | 1987-08-21 | 1994-04-26 | University Of Colorado Foundation, Inc. | Compositions and method for inhibition of HIV production |
WO1989001973A2 (en) * | 1987-09-02 | 1989-03-09 | Applied Biotechnology, Inc. | Recombinant pox virus for immunization against tumor-associated antigens |
US5175385A (en) * | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
US5246924A (en) * | 1987-09-03 | 1993-09-21 | Sloan-Kettering Institute For Cancer Research | Method for treating hepatitis B virus infections using 1-(2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl)-5-ethyluracil |
DE3852823T2 (de) * | 1987-09-11 | 1995-05-24 | Whitehead Biomedical Inst | Transduktionsveränderte fibroblasten und ihre anwendung. |
WO1989005349A1 (en) * | 1987-12-09 | 1989-06-15 | The Australian National University | Method of combating viral infections |
EP0391960B1 (de) * | 1987-12-11 | 1994-08-17 | Whitehead Institute For Biomedical Research | Genetische modifizierung von endothelialen zellen |
AU3069189A (en) * | 1988-02-05 | 1989-08-25 | Trustees Of Columbia University In The City Of New York, The | Retroviral packaging cell lines and processes of using same |
CN1038306A (zh) * | 1988-03-21 | 1989-12-27 | 维吉恩公司 | 重组反转录病毒 |
JPH0797997B2 (ja) * | 1988-04-28 | 1995-10-25 | 帝人株式会社 | 新規生理活性ポリペプチド |
EP0437610B1 (de) * | 1988-09-22 | 1996-06-12 | Teijin Limited | Physiologisch aktives polypeptid, rekombinantes plasmid, rekombinante mikrobielle zellen, medizinisches präparat sowie verfahren zur gewinnung des gereinigten polypeptids |
DE3841762A1 (de) * | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
US5399346A (en) * | 1989-06-14 | 1995-03-21 | The United States Of America As Represented By The Department Of Health And Human Services | Gene therapy |
US5126132A (en) * | 1989-08-21 | 1992-06-30 | The United States Of America As Represented By The Department Of Health And Human Services | Tumor infiltrating lymphocytes as a treatment modality for human cancer |
US5032519A (en) * | 1989-10-24 | 1991-07-16 | The Regents Of The Univ. Of California | Method for producing secretable glycosyltransferases and other Golgi processing enzymes |
ATE199398T1 (de) * | 1989-10-24 | 2001-03-15 | Chiron Corp | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein |
US5281475A (en) * | 1991-10-17 | 1994-01-25 | W. L. Gore & Associates, Inc. | Continuous polytetrafluoroethylene fibers |
GB2268853A (en) * | 1992-07-09 | 1994-01-19 | Secr Defence | Colour television display projection device |
-
1990
- 1990-10-23 AT AT98112614T patent/ATE199398T1/de active
- 1990-10-23 DE DE69033710T patent/DE69033710T2/de not_active Expired - Fee Related
- 1990-10-23 WO PCT/US1990/006141 patent/WO1991006658A2/en active IP Right Grant
- 1990-10-23 EP EP91901031A patent/EP0497922B1/de not_active Expired - Lifetime
- 1990-10-23 EP EP98112614A patent/EP0897987B1/de not_active Expired - Lifetime
- 1990-10-23 DE DE69033911T patent/DE69033911D1/de not_active Expired - Fee Related
- 1990-10-23 AU AU69566/91A patent/AU661652B2/en not_active Ceased
- 1990-10-23 CA CA002067821A patent/CA2067821A1/en not_active Abandoned
- 1990-10-23 JP JP50142591A patent/JP3203599B2/ja not_active Expired - Fee Related
- 1990-10-23 AT AT91901031T patent/ATE212672T1/de not_active IP Right Cessation
-
1992
- 1992-02-18 US US07/839,017 patent/US5324655A/en not_active Expired - Fee Related
-
1994
- 1994-06-06 US US08/237,783 patent/US6071512A/en not_active Expired - Fee Related
-
1995
- 1995-05-24 US US08/449,689 patent/US5889156A/en not_active Expired - Fee Related
- 1995-05-24 US US08/448,897 patent/US5863797A/en not_active Expired - Fee Related
- 1995-05-24 US US08/448,889 patent/US5874077A/en not_active Expired - Fee Related
- 1995-06-05 US US08/464,315 patent/US5849586A/en not_active Expired - Fee Related
- 1995-11-03 AU AU36646/95A patent/AU3664695A/en not_active Abandoned
-
2000
- 2000-03-07 JP JP2000062754A patent/JP2000270883A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH05504681A (ja) | 1993-07-22 |
EP0897987A3 (de) | 1999-03-03 |
AU661652B2 (en) | 1995-08-03 |
EP0897987B1 (de) | 2001-02-28 |
WO1991006658A3 (en) | 1991-10-17 |
US5849586A (en) | 1998-12-15 |
EP0497922A1 (de) | 1992-08-12 |
EP0497922B1 (de) | 2002-01-30 |
US5324655A (en) | 1994-06-28 |
US5889156A (en) | 1999-03-30 |
DE69033911D1 (de) | 2002-03-14 |
JP2000270883A (ja) | 2000-10-03 |
EP0897987A2 (de) | 1999-02-24 |
AU3664695A (en) | 1996-03-21 |
WO1991006658A2 (en) | 1991-05-16 |
ATE212672T1 (de) | 2002-02-15 |
US6071512A (en) | 2000-06-06 |
AU6956691A (en) | 1991-05-31 |
DE69033710D1 (de) | 2001-04-12 |
DE69033710T2 (de) | 2001-06-13 |
JP3203599B2 (ja) | 2001-08-27 |
US5874077A (en) | 1999-02-23 |
US5863797A (en) | 1999-01-26 |
CA2067821A1 (en) | 1991-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE199398T1 (de) | Sekretion vom mit gamma-interferon signalpeptid gebundenen humänen protein | |
ATE122397T1 (de) | Fusionsproteine aus interleukin-2 und hirudin. | |
ES2080098T3 (es) | Expresion de la proteina de union i al factor de necrosis tumoral tbp-i recombinante. | |
DE3672924D1 (de) | Cystein verminderte muteine von biologisch aktiven menschlichen tnf-proteinen. | |
DE3881776D1 (de) | Dns-konstruktionen, enthaltend eine kluyveromyces-alpha-factor-leadersequenz zur leitung der sekretion von heterologen polypeptiden. | |
FR2514783B1 (fr) | Interferon immunitaire humain | |
ATA257190A (de) | Virales polypeptid | |
DK134790D0 (da) | Dna, der koder ige receptor alfa-subenhed eller fragment heraf | |
SE9101433D0 (sv) | Recombinant dna sequence and its use | |
ATE84798T1 (de) | Transformierender wachstumsfaktor-beta. | |
DE3786649D1 (de) | Pferde-gamma-interferon. | |
IL87391A0 (en) | Hiv proteins and peptides,dna coding therefor,vectors comprising such dna,the use of the proteins and peptides in diagnosis of aids and vaccine compositions containing them | |
DE3881023D1 (de) | Proteine, expressionsvektoren, die fuer solche proteine kodierende dna enthalten und zellen, die solche expressionsvektoren enthalten. | |
NO873216L (no) | Rekombinante htlv-iii-proteiner og anvendelse derav. | |
AU8755591A (en) | Gro genes, proteins, and uses thereof | |
EP0620860A4 (en) | Preparation of recombinant borrelia proteins. | |
IL90134A (en) | Recombinant dna molecule encoding for plasmodium falciparum surface protein of zygotes and ookinetes and pharmaceutical compositions containing said protein prepared by expressing said dna | |
DE3881123D1 (de) | Klonieren von fuer einen antibakteriellen polypeptidvorlaeufer kodierender dna und expression des vorlaeufers. | |
ATE254179T1 (de) | Neue type-i-interferon varianten, ihre verfahren zur herstellung, und ihre verwendungen | |
FR2481316B1 (fr) | Technique a adn de recombinant pour la preparation d'une proteine ressemblant a l'interferon humain | |
FI895456A0 (fi) | Rekombinant interleukin 2-hybridproteiner. | |
ATE111920T1 (de) | Lymphokine, dns-sequenzen, die diese lymphokine kodieren, und sie enthaltende pharmazeutische zusammensetzungen. | |
ITFI920071A1 (it) | Antigeni ricombinanti proteici ad aumentata immunogenicita' contenenti il peptide rappresentato dalla sequenza vqgeesndk | |
NO875477D0 (no) | Rekombinant alveolaert overflateaktivt protein. | |
ES2090019T3 (es) | Preparacion por tecnologia genetica de proteina pp15. |